Verve Therapeutics’ (VERV) Buy Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Verve Therapeutics (NASDAQ:VERV) in a research note issued to investors on Monday, Benzinga reports. The brokerage currently has a $15.00 price target on the stock.

VERV has been the subject of a number of other research reports. Canaccord Genuity Group decreased their price target on shares of Verve Therapeutics from $30.00 to $29.00 and set a buy rating for the company in a report on Monday. Royal Bank of Canada decreased their price target on shares of Verve Therapeutics from $25.00 to $20.00 and set an outperform rating for the company in a report on Friday, August 9th. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of Moderate Buy and an average target price of $25.20.

Verve Therapeutics Stock Up 3.2 %

NASDAQ:VERV opened at $4.54 on Monday. Verve Therapeutics has a 52 week low of $4.30 and a 52 week high of $20.12. The firm has a 50 day moving average of $5.88 and a 200 day moving average of $8.49. The stock has a market capitalization of $381.20 million, a price-to-earnings ratio of -1.58 and a beta of 1.84.

Verve Therapeutics (NASDAQ:VERV) last posted its earnings results on Thursday, August 8th. The company reported ($0.59) EPS for the quarter, beating analysts’ consensus estimates of ($0.68) by $0.09. Verve Therapeutics had a negative net margin of 933.08% and a negative return on equity of 35.20%. The company had revenue of $6.70 million during the quarter, compared to analysts’ expectations of $2.40 million. During the same quarter in the prior year, the company posted ($0.87) earnings per share. Verve Therapeutics’s revenue for the quarter was up 219.0% compared to the same quarter last year. As a group, analysts expect that Verve Therapeutics will post -2.73 EPS for the current year.

Institutional Trading of Verve Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the business. PNC Financial Services Group Inc. acquired a new stake in shares of Verve Therapeutics in the fourth quarter worth $29,000. Newbridge Financial Services Group Inc. acquired a new stake in shares of Verve Therapeutics in the fourth quarter worth $30,000. Quest Partners LLC acquired a new stake in shares of Verve Therapeutics in the fourth quarter worth $34,000. Nisa Investment Advisors LLC increased its stake in shares of Verve Therapeutics by 908.4% in the second quarter. Nisa Investment Advisors LLC now owns 7,714 shares of the company’s stock worth $38,000 after acquiring an additional 6,949 shares during the period. Finally, Daiwa Securities Group Inc. increased its stake in shares of Verve Therapeutics by 89.8% in the second quarter. Daiwa Securities Group Inc. now owns 12,094 shares of the company’s stock worth $59,000 after acquiring an additional 5,723 shares during the period. Institutional investors and hedge funds own 97.11% of the company’s stock.

Verve Therapeutics Company Profile

Verve Therapeutics, Inc, a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH.